DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
The generic ingredient in UKONIQ is umbralisib tosylate. Additional details are available on the umbralisib tosylate profile page.
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 213176
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||TABLET;ORAL||Strength||EQ 200MG BASE|
|Approval Date:||Feb 5, 2021||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Feb 5, 2028|
|Regulatory Exclusivity Use:|
|Regulatory Exclusivity Expiration:||Feb 5, 2026|
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
|Patent:||⤷ Try it Free||Patent Expiration:||Jul 2, 2033||Product Flag?||Substance Flag?||Delist Request?|
|Patented Use:||RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY|
Complete Access Available with Subscription